Nathan downhour interview, Medicare post-PHE update, Drug Watch list and FDA decisions
April 19, 2023
|
Weekly Prime client digest
|
In addition to the corporate client emails you receive, provided is a weekly digest that bundles information and reminders for your convenience. |
Interview with Prime's Nathan Downhour |
Relevant for all lines of business
Nathan Downhour, Prime's senior vice president of health care services, talks Prime's clinical products and programs, what makes us different from the big three PBMs and more. |
|
|
Drug watch list - April |
Relevant for all lines of business
Prime publishes a monthly drug watch list to proactively communicate to clients the most notable drugs that may significantly affect the populations we serve. |
|
May decisions expected from the FDA |
Relevant for all lines of business
At Prime, we’ve positioned ourselves to best prepare our clients to manage new drugs. In this article, our clinical and trade relations teams outline drugs likely to be approved by the U.S. Food and Drug Administration (FDA). |
|
|
For feedback or questions on corporate client communications, please contact clientcommunications@primetherapeutics.com.
To access additional Prime client communications and resources, check out the Prime Client Portal. If you don't have access to the portal, contact your IT administrator to request access just as you would to access any Prime application. |
|
|